Photo: AFP / Jens Kalaene
Pharmac is seeking clinical advice on whether weight loss medication should be funded.
New Zealand has the third-highest adult obesity rate in the Organisation for Economic Co-operation and Development (OECD).
One in three people over the age of 15 are classified as obese and one in eight children aged between 2-14.
Pharmac received two applications to fund Wegovy or semaglutide - a GLP-1 receptor agonist for weight loss.
The first was in September, for people with an established cardiovascular disease (such as someone who has
Continue Reading on RNZ
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.